Primary Open Angle Glaucoma Clinical Trial Pipeline: Emerging Therapies Shaping the Future of Treatment | DelveInsight

The treatment landscape for Primary Open Angle Glaucoma (POAG), a leading cause of blindness worldwide, is undergoing significant transformation, driven by cutting-edge therapies from top pharmaceutical and biotechnology companies. Key players in the field, like Santen Pharmaceutical Co., Ltd., PH PHARMA., Whitecap Biosciences, and Ocular Therapeutix, are focusing on developing novel therapeutics that target multiple mechanisms underlying POAG, including intraocular pressure (IOP) reduction, optic nerve protection, and neuroprotection. These emerging therapies aim to enhance disease management, reduce progression to blindness, and improve the quality of life for patients with POAG.

DelveInsight's "Primary Open Angle Glaucoma - Pipeline Insight, 2025" offers a thorough analysis of the current clinical development landscape, highlighting investigational drugs in various stages, from early preclinical studies to advanced Phase III trials. The report explores the mechanisms of action of each drug, development statuses, and anticipated timelines for market availability.
This pipeline insight provides a holistic 360° view of POAG therapeutic trends, including drug types, administration routes, and clinical phases. Furthermore, it examines unmet needs, strategic partnerships, regulatory designations, and market dynamics expected to shape the POAG treatment paradigm in the coming years.

Interested in learning more about the current treatment landscape and the key drivers shaping the POAG pipeline? Click here: https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Primary Open Angle Glaucoma Pipeline Report
• DelveInsight's primary open-angle glaucoma pipeline analysis depicts a strong space with 8+ active players working to develop 8+ pipeline drugs for primary open-angle glaucoma treatment.
• The leading primary open-angle glaucoma companies include Santen Pharmaceutical, PH PHARMA, Whitecap Biosciences, Ocular Therapeutix, TheratOcular Biotek, and others are evaluating their lead assets to improve the primary open-angle glaucoma treatment landscape.
• Key primary open-angle glaucoma pipeline therapies in various stages of development include STN1012600, PHP-201, WB007, OTX-TIC, TO-O-1001, and others.
• In April 2025, BVI Medical received FDA 510(k) clearance for its innovative LeosTM Laser Endoscopy Ophthalmic System, a new glaucoma surgical device.
• In April 2025, Perfuse Therapeutics, Inc. announced the results of a Phase I/IIa study evaluating the safety, tolerability, and pharmacodynamic effects following a single administration of the PER-001 intravitreal implant in participants with open-angle glaucoma.
• In March 2025, Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), a global ophthalmology company, revealed that the final patient had completed their last visit in the Whistler Phase IIIb trial. This trial evaluates NCX 470's dual mechanism of action-nitric oxide and prostaglandin analog-for reducing intraocular pressure (IOP). NCX 470, Nicox's lead clinical candidate, is an innovative NO-donating bimatoprost eye drop currently in Phase III development for treating open-angle glaucoma and ocular hypertension.
• In February 2025, Qlaris Bio, Inc., a clinical-stage biotechnology company focused on unmet ophthalmic needs, reported positive topline results from two U.S. Phase II trials evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Both Phase II studies, Osprey and Apteryx, achieved all primary and secondary endpoints successfully.
• In January 2025, Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceuticals and medical technologies for glaucoma, launched a Phase IIb/III clinical program for iDose TREX, its next-generation sustained-release therapeutic platform. iDose TREX, designed to resemble the original iDose TR in size and shape, offers nearly double the drug capacity.
• In December 2024, Glaukos Corporation (NYSE: GKOS) announced the submission of its New Drug Application (NDA) to the FDA for EPIOXATM (EPI-ON), a next-generation corneal cross-linking therapy for treating keratoconus, a progressive corneal disease.
• In October 2024, at the American Academy of Ophthalmology (AAO) 2024 conference in Chicago, Illinois, findings from a Phase II study on Neurotech Pharmaceuticals' NT-501 encapsulated cell therapy were presented. The therapy, which secretes ciliary neurotrophic factor (CNTF), was studied for neuroprotection in glaucoma patients. Results showed that CNTF-secreting implants were well-tolerated in primary open-angle glaucoma patients, with no severe adverse events reported.
• In March 2024, MediPrint Registered Ophthalmics announced the successful completion of its Phase IIb glaucoma clinical study with positive results.
• In February 2024, Skye Bioscience completed enrollment of its Phase IIa clinical trial of SBI-100 ophthalmic emulsion in glaucoma and ocular hypertension.

Request a sample and discover the recent breakthroughs happening in the primary open-angle glaucoma pipeline landscape @ https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Primary Open Angle Glaucoma Overview
Primary open-angle glaucoma is a condition characterized by optic nerve damage, which is often associated with an open anterior chamber angle and either elevated or sometimes average intraocular pressure (IOP). The condition can be classified into two forms: adult-onset glaucoma, which develops after the age of 40, and juvenile-onset glaucoma, which occurs between the ages of 3 and 40. The disease typically arises from an issue within the eye's natural drainage system, which regulates the flow of fluid. If a blockage occurs or fluid is produced faster than it can escape, the pressure within the eye rises, damaging the optic nerve.

In most cases, primary open-angle glaucoma develops without symptoms in its early stages. Since peripheral vision is affected first and the other eye compensates for the loss, patients often do not notice visual changes until significant and permanent damage has already occurred, typically impacting central vision. By this stage, up to 90% of the optic nerve fibers may be irreparably damaged. Left untreated, glaucoma can progress to irreversible blindness.

The risk of developing primary open-angle glaucoma is higher among individuals with certain factors. Key risk factors include older age, a family history of the disease, African ethnicity, thinner central corneal thickness, systemic hypertension, diabetes, and myopia. Although there is some evidence linking primary open-angle glaucoma to other conditions like elevated systolic blood pressure and migraines, these risk factors are less consistently proven.

Find out more about primary open-angle glaucoma medication @ https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Primary Open Angle Glaucoma Treatment Analysis: Drug Profile
STN1012600: Santen Pharmaceutical Co., Ltd.
STN1012600 is an investigational prostaglandin analogue eye drop that functions as a dual agonist for both FP and EP3 receptors, targeting glaucoma and ocular hypertension. This therapy completed a Phase II trial in the U.S. in December 2021 and initiated a Phase III trial in Japan in August 2022, focusing on patients with Primary Open-Angle Glaucoma and Ocular Hypertension.

TO-O-1001: TheratOcular Biotek Co., Ltd.
TO-O-1001 (formerly known as MG-O-1001) is a novel Rho kinase (ROCK) inhibitor eye drop for the treatment of Primary Open-Angle Glaucoma (POAG) and ocular hypertension. By targeting both the trabecular meshwork cells and Schlemm's canal, it promotes increased aqueous humor outflow, effectively lowering intraocular pressure. Known for its innovative mechanism, it is also user-friendly with a once-daily dosage. Currently, TO-O-1001 is undergoing Phase I/II trials to evaluate its safety, tolerability, and efficacy for treating POAG.

Learn more about the novel and emerging primary open-angle glaucoma pipeline therapies @ https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Primary Open Angle Glaucoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Primary Open Angle Glaucoma Pipeline Report
• Coverage: Global
• Key Primary Open Angle Glaucoma Companies: Santen Pharmaceutical Co., Ltd., PH PHARMA CO. LTD., Whitecap Biosciences, LLC, Ocular Therapeutix, Inc., TheratOcular Biotek Co., Ltd., and others.
• Key Primary Open Angle Glaucoma Pipeline Therapies: STN1012600, PHP-201, WB007, OTX-TIC, TO-O-1001, and others.

Dive deep into rich insights for drugs used for primary open-angle glaucoma treatment; visit @ https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Primary Open Angle Glaucoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Primary Open Angle Glaucoma Pipeline Therapeutics
6. Primary Open Angle Glaucoma Pipeline: Late-Stage Products (Phase III)
7. Primary Open Angle Glaucoma Pipeline: Mid-Stage Products (Phase II)
8. Primary Open Angle Glaucoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.